Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Allergy
Published in: Clinical and Translational Allergy 1/2012

Open Access 01-12-2012 | Position article and guidelines

EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy

Authors: Moises A Calderon, Pascal Demoly, Roy Gerth van Wijk, Jean Bousquet, Aziz Sheikh, Anthony Frew, Glenis Scadding, Claus Bachert, Hans J Malling, Rudolph Valenta, Beatrice Bilo, Antonio Nieto, Cezmi Akdis, Jocelyne Just, Carmen Vidal, Eva M Varga, Emilio Alvarez-Cuesta, Barbara Bohle, Albrecht Bufe, Walter G Canonica, Victoria Cardona, Ronald Dahl, Alain Didier, Stephen R Durham, Peter Eng, Montserrat Fernandez-Rivas, Lars Jacobsen, Marek Jutel, Jörg Kleine-Tebbe, Ludger Klimek, Jan Lötvall, Carmen Moreno, Ralph Mosges, Antonella Muraro, Bodo Niggemann, Giovanni Pajno, Giovanni Passalacqua, Oliver Pfaar, Sabina Rak, Gianenrico Senna, Gabriela Senti, Erkka Valovirta, Marianne van Hage, Johannes C Virchow, Ulrich Wahn, Nikolaos Papadopoulos

Published in: Clinical and Translational Allergy | Issue 1/2012

Login to get access

Abstract

Allergy today is a public health concern of pandemic proportions, affecting more than 150 million people in Europe alone. In view of epidemiological trends, the European Academy of Allergy and Clinical Immunology (EAACI) predicts that within the next few decades, more than half of the European population may at some point in their lives experience some type of allergy.
Not only do allergic patients suffer from a debilitating disease, with the potential for major impact on their quality of life, career progression, personal development and lifestyle choices, but they also constitute a significant burden on health economics and macroeconomics due to the days of lost productivity and underperformance. Given that allergy triggers, including urbanization, industrialization, pollution and climate change, are not expected to change in the foreseeable future, it is imperative that steps are taken to develop, strengthen and optimize preventive and treatment strategies.
Allergen specific immunotherapy is the only currently available medical intervention that has the potential to affect the natural course of the disease. Years of basic science research, clinical trials, and systematic reviews and meta-analyses have convincingly shown that allergen specific immunotherapy can achieve substantial results for patients, improving the allergic individuals’ quality of life, reducing the long-term costs and burden of allergies, and changing the course of the disease. Allergen specific immunotherapy not only effectively alleviates allergy symptoms, but it has a long-term effect after conclusion of the treatment and can prevent the progression of allergic diseases.
Unfortunately, allergen specific immunotherapy has not yet received adequate attention from European institutions, including research funding bodies, even though this could be a most rewarding field in terms of return on investments, translational value and European integration and, a field in which Europe is recognized as a worldwide leader. Evaluation and surveillance of the full cost of allergic diseases is still lacking and further progress is being stifled by the variety of health systems across Europe. This means that the general population remains unaware of the potential use of allergen specific immunotherapy and its potential benefits.
We call upon Europe’s policy-makers to coordinate actions and improve individual and public health in allergy by:
  • Promoting awareness of the effectiveness of allergen specific immunotherapy
  • Updating national healthcare policies to support allergen specific immunotherapy
  • Prioritising funding for allergen specific immunotherapy research
  • Monitoring the macroeconomic and health economic parameters of allergy
  • Reinforcing allergy teaching in medical disciplines and specialties
The effective implementation of the above policies has the potential for a major positive impact on European health and well-being in the next decade.
Literature
1.
Asher MI, Montefort S, Björkstén B, Lai CK, Strachan DP, Weiland SK, Williams H: Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys.; ISAAC Phase Three Study Group. Lancet. 2006, 368 (9537): 733-743. 10.1016/S0140-6736(06)69283-0.CrossRefPubMed
2.
Pearce N, Ait-Khaled N, Beasley R, Mallol J, Keil U, Mitchell E: Worldwide trends in the prevalence of asthma symptoms: phase III of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax. 2007, 62: 758-766. 10.1136/thx.2006.070169.PubMedCentralCrossRefPubMed
3.
Jarvis D, Newson R, Lotvall J, Hastan D, Tomassen P, Keil T, Gjomarkaj M, Forsberg B, Gunnbjornsdottir M, Minov J, Brozek G, Dahlen SE, Toskala E, Kowalski ML, Olze H, Howarth P, Krämer U, Baelum J, Loureiro C, Kasper L, Bousquet PJ, Bousquet J, Bachert C, Fokkens W, Burney P: Asthma in adults and its association with chronic rhinosinusitis: The GA2LEN survey in Europe. Allergy. 2012, 67: 91-98. 10.1111/j.1398-9995.2011.02709.x.CrossRefPubMed
4.
Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A: Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen).; World Health Organization; GA(2)LEN; AllerGen. Allergy. 2008, 63 (Suppl 86): 8-160.CrossRefPubMed
5.
Wallace DV, Dykewicz MS, Bernstein DI, Blessing-Moore J, Cox L, Khan DA: The diagnosis and management of rhinitis: an updated practice parameter. Joint Task Force on Practice; American Academy of Allergy; Asthma & Immunology; American College of Allergy; Asthma and Immunology; Joint Council of Allergy, Asthma and Immunology. J Allergy Clin Immunol. 2008, 122 (2 Suppl): S1-S84.CrossRefPubMed
6.
World Health Organization (WHO): Fact sheet No. 307 on Asthma. 2011
7.
Punekar YS, Sheikh A: Establishing the incidence and prevalence of clinician-diagnosed allergic conditions in children and adolescents using routinely collected data from general practices. Clin Exp Allergy. 2009, 39 (8): 1209-1216. 10.1111/j.1365-2222.2009.03248.x.CrossRefPubMed
8.
Isolauri E, Huurre A, Salminem S, Impivaara O: The allergy epidemic extends beyond the past two decades. Clin Exp Allergy. 2004, 34: 1007-1010. 10.1111/j.1365-2222.2004.01999.x.CrossRefPubMed
9.
10.
Grize L, Gassner M, Wüthrich B, Bringolf-Isler B, Takken-Sahli K, Sennhauser FH: Trends in prevalence of asthma, allergic rhinitis and atopic dermatitis in 5–7-year old Swiss children from 1992 to 2001. Allergy. 2006, 61 (5): 556-562. 10.1111/j.1398-9995.2006.01030.x.CrossRefPubMed
11.
Smith JA, Drake R, Simpson A, Woodcock A, Pickles A, Custovic A: Dimensions of respiratory symptoms in preschool children: population-based birth cohort study. Am J Respir Crit Care Med. 2008, 177 (12): 1358-1363. 10.1164/rccm.200709-1419OC.CrossRefPubMed
12.
Anandan C, Nurmatov U, van Schayck OC, Sheikh A: Is the prevalence of asthma declining? Systematic review of epidemiological studies. Allergy. 2010, 65 (2): 152-167. 10.1111/j.1398-9995.2009.02244.x.CrossRefPubMed
13.
Siroux V, Boudier A, Anto JM, Cazzoletti L, Accordini S, Alonso J: Quality-of-life and asthma-severity in general population asthmatics: results of the ECRHS II study. Allergy. 2008, 63 (5): 547-554. 10.1111/j.1398-9995.2008.01638.x.CrossRefPubMed
14.
Walker S, Khan-Wasti S, Fletcher M, Cullinan P, Harris J, Sheikh A: Seasonal allergic rhinitis is associated with a detrimental effect on examination performance in United Kingdom teenagers: case–control study. J Allergy Clin Immunol. 2007, 120: 381-387. 10.1016/j.jaci.2007.03.034.CrossRefPubMed
15.
Bousquet J, Neukirch F, Bousquet PJ, Gehano P, Klossek JM, Le Gal M: Severity and impairment of allergic rhinitis in patients consulting in primary care. J Allergy Clin Immunol. 2006, 117: 158-162. 10.1016/j.jaci.2005.09.047.CrossRefPubMed
16.
Stuck BA, Czaijkowski J, Hagner AE, Klimek L, Verse T, Hörmann K: Changes in daytime sleepiness, quality of life, and objective sleep patterns in seasonal allergic rhinitis: a controlled clinical trial. J Allergy Clin Immunol. 2004, 113: 663-668. 10.1016/j.jaci.2003.12.589.CrossRefPubMed
17.
Baiardini I, Braido F, Tarantini F, Porcu A, Bonini S, Bousquet PJ: ARIA-suggested drugs for allergic rhinitis: what impact on quality of life? A GA2LEN review. Allergy. 2008, 63 (6): 660-669. 10.1111/j.1398-9995.2008.01649.x.CrossRefPubMed
18.
Bachert C, Bousquet J, Canonica GW, Durham SR: The XPERTTM study group. XPERTTM Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis. J Allergy Clin Immunol. 2004, 114: 838-844. 10.1016/j.jaci.2004.05.070.CrossRefPubMed
19.
Virchow JC, Kay S, Demoly P, Mullol J, Canonica W, Higgins V: Impact of ocular symptoms on quality of life (QoL), work productivity and resource utilisation in allergic rhinitis patients – an observational, cross sectional study in four countries in Europe. J Med Econ. 2011, 14 (3): 305-314. 10.3111/13696998.2011.576039.CrossRefPubMed
20.
Wertz DA, Pollack M, Rodgers K, Bohn RL, Sacco P, Sullivan SD: Impact of asthma control on sleep, attendance at work, normal activities, and disease burden. Ann Allergy Asthma Immunol. 2010, 105 (2): 118-123. 10.1016/j.anai.2010.05.009.CrossRefPubMed
21.
Lefevre F, Moreau D, Sémon E, Kalaboka S, Annesi-Maesano I, Just J: Maternal depression related to infant's wheezing. Pediatr Allergy Immunol. 2011, 22 (6): 608-613. 10.1111/j.1399-3038.2011.01155.x.CrossRefPubMed
22.
Gupta R, Sheikh A, Strachan DP, Anderson HR: Burden of allergic disease in the UK: secondary analyses of national databases. Clin Exp Allergy. 2004, 34 (4): 520-526. 10.1111/j.1365-2222.2004.1935.x.CrossRefPubMed
23.
Anandan C, Gupta R, Simpson CR, Fischbacher C, Sheikh A: Epidemiology and disease burden from allergic disease in Scotland: analyses of national databases. J R Soc Med. 2009, 102 (10): 431-442. 10.1258/jrsm.2009.090027.PubMedCentralCrossRefPubMed
24.
European Respiratory Society (ERS): European Lung White Book. The First Comprehensive Survey on Respiratory Health in Europe. 2003
25.
Accordini S, Corsico A, Cerveri I, Gislason D, Gulsvik A, Janson C: The socio-economic burden of asthma is substantial in Europe. Allergy. 2008, 63 (1): 116-124.CrossRefPubMed
26.
Sullivan SD, Turk F: An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma. Allergy. 2008, 63: 670-684. 10.1111/j.1398-9995.2008.01723.x.CrossRefPubMed
27.
Bousquet J, Demarteau N, Mullol J, van den Akker-van Marle ME, Van Ganse E, Bachert C: Costs associated with persistent allergic rhinitis are reduced by levocetirizine. Allergy. 2005, 60: 788-794. 10.1111/j.1398-9995.2005.00820.x.CrossRefPubMed
28.
Zuberbier T, Lötvall J: Allergies have a socio-economic impact. European academy of allergology and clinical immunology, annual meeting 2008. Allergy. 2008, 63 (Suppl. 84): 280-
29.
Reed SD, Lee TA, McCrory DC: The economic burden of allergic rhinitis: a critical evaluation of the literature. PharmacoEconomics. 2004, 22 (6): 345-361. 10.2165/00019053-200422060-00002.CrossRefPubMed
30.
Nasser S, Vestenbaek U, Beriot-Mathiot A, Poulsen PB: Cost-effectiveness of specific immunotherapy with Grazax in allergic rhinitis co-existing with asthma. Allergy. 2008, 63: 1624-1629. 10.1111/j.1398-9995.2008.01743.x.CrossRefPubMed
31.
Guilbert TW, Morgan WJ, Zeiger RS, Mauger DT, Boehmer SJ, Szefler SJ: Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med. 2006, 354 (19): 1985-1997. 10.1056/NEJMoa051378.CrossRefPubMed
32.
Marinho S, Simpson A, Custovic A: Allergen avoidance in the secondary and tertiary prevention of allergic diseases: does it work?. Prim Care Respir J. 2006, 15 (3): 152-158. 10.1016/j.pcrj.2006.02.005.CrossRefPubMed
33.
Phan H, Moeller ML, Nahata MC: Treatment of allergic rhinitis in infants and children: efficacy and safety of second-generation antihistamines and the leukotriene receptor antagonist montelukast. Drugs. 2009, 69 (18): 2541-2576. 10.2165/9884960-000000000-00000.CrossRefPubMed
34.
Murray CS, Woodcock A, Langley SJ, Morris J, Custovic A: IFWIN study team. Secondary prevention of asthma by the use of Inhaled Fluticasone propionate in Wheezy INfants (IFWIN): double-blind, randomised, controlled study. Lancet. 2006, 368 (9537): 754-762. 10.1016/S0140-6736(06)69285-4.CrossRefPubMed
35.
White P, Smith H, Baker N, Davis W, Frew A: Symptom control in patients with hay fever in UK general practice: how well are we doing and is there a need for allergen immunotherapy?. Clin Exp Allergy. 1998, 28 (3): 266-270. 10.1046/j.1365-2222.1998.00237.x.CrossRefPubMed
36.
Allen DB: Effects of inhaled steroids on growth, bone metabolism, and adrenal function. Adv Pediatr. 2006, 53: 101-110. 10.1016/j.yapd.2006.04.006.CrossRefPubMed
37.
Layton D, Wilton L, Boshier A, Cornelius V, Harris S, Shakir SA: Comparison of the risk of drowsiness and sedation between levocetirizine and desloratadine: a prescription-event monitoring study in England. Drug Saf. 2006, 29 (10): 897-909. 10.2165/00002018-200629100-00007.CrossRefPubMed
38.
Passalacqua G, Bousquet PJ, Carlsen KH, Kemp J, Lockey RF, Niggemann B, Pawankar R, Price D, Bousquet J: ARIA update: I–Systematic review of complementary and alternative medicine for rhinitis and asthma. J Allergy Clin Immunol. 2006, 117 (5): 1054-1062. 10.1016/j.jaci.2005.12.1308.CrossRefPubMed
39.
Council of the European Union: Review of the EU Sustainable Developmental Strategy (EU SDS): Renewed Strategy. 2006, 10917/06
40.
Abramson MJ, Puy RM, Weiner JM: Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev. 2010, 4 (8): CD001186-
41.
Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S: Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev. 2007, 24 (1): CD001936-
42.
Radulovic S, Calderon MA, Wilson D, Durham S: Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev. 2010, 8 (12): CD002893-
43.
Calderon MA, Penagos M, Sheikh A, Canonica GW, Durham SR: Sublingual immunotherapy for allergic conjunctivitis: Cochrane systematic review and meta-analysis. Clin Exp Allergy. 2011, 41 (9): 1263-1272. 10.1111/j.1365-2222.2011.03835.x.CrossRefPubMed
44.
Durham SR, Walker SM, Varga EM, Jacobson MR, O'Brien F, Noble W, Till SJ, Hamid QA, Nouri-Aria KT: Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med. 1999, 341 (7): 468-475. 10.1056/NEJM199908123410702.CrossRefPubMed
45.
Durham SR, Emminger W, Kapp A, Colombo G, de Monchy JG, Rak S, Scadding GK, Andersen JS, Riis B, Dahl R: Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. J. Allergy Clin Immunol. 2010, 125 (1): 131-138. 10.1016/j.jaci.2009.10.035.CrossRefPubMed
46.
Durham SR, Emminger W, Kapp A, de Monchy JG, Rak S, Scadding GK, Wurtzen PA, Andersen JS, Tholstrup B, Riis B, Dahl R: SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol. 2012, 129 (3): 717-725. 10.1016/j.jaci.2011.12.973.CrossRefPubMed
47.
Jacobsen L, Niggemann B, Dreborg S, Ferdousi HA, Halken S, Høst A, Koivikko A, Norberg LA, Valovirta E, Wahn U, Möller C, The PAT investigator group: Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy. 2007, 62 (8): 943-948. 10.1111/j.1398-9995.2007.01451.x.CrossRefPubMed
48.
Eng PA, Borer-Reinhold M, Heijnen IA, Gnehm HP: Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood. Allergy. 2006, 61 (2): 198-201. 10.1111/j.1398-9995.2006.01011.x.CrossRefPubMed
49.
Novembre E, Galli E, Landi F, Caffarelli C, Pifferi M, De Marco E, Burastero SE, Calori G, Benetti L, Bonazza P, Puccinelli P, Parmiani S, Bernardini R, Vierucci A: Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2004, 114 (4): 851-857. 10.1016/j.jaci.2004.07.012.CrossRefPubMed
50.
Marogna M, Spadolini I, Massolo A, Canonica GW, Passalacqua G: Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study. J Allergy Clin Immunol. 2010, 126 (5): 969-975. 10.1016/j.jaci.2010.08.030.CrossRefPubMed
51.
Canonica GW, Bousquet J, Casale T: Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy. 2009, 64 (Suppl 91): 1-59.PubMed
52.
Noon L, Cantab BC: Prophylactic inoculation against hay fever. Lancet. 1911, 177 (4580): 1572-1573. 10.1016/S0140-6736(00)78276-6.CrossRef
53.
Bousquet J, Lockey R, Malling HJ: Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol. 1998, 102 (4 Pt 1): 558-562.CrossRefPubMed
54.
Passalacqua G, Compalati E, Canonica GW: Advances in allergen-specific immunotherapy. Curr Drug Targets. 2009, 10 (12): 1255-1262. 10.2174/138945009789753237.CrossRefPubMed
55.
Bousquet PJ, Calderón MA, Demoly P, Larenas D, Passalacqua G, Bachert C, Brozek J, Canonica GW, Casale T, Fonseca J, Dahl R, Durham SR, Merk H, Worm M, Wahn U, Zuberbier T, Schünemann HJ, Bousquet J: The Consolidated Standards of Reporting Trials (CONSORT) Statement applied to allergen-specific immunotherapy with inhalant allergens: a Global Allergy and Asthma European Network (GA(2)LEN) article. J Allergy Clin Immunol. 2011, 127 (1): 49-56. 10.1016/j.jaci.2010.09.017.CrossRefPubMed
56.
Bousquet J, Schünemann HJ, Bousquet PJ, Bachert C, Canonica GW, Casale TB, Demoly P, Durham S, Carlsen KH, Malling HJ, Passalacqua G, Simons FE, Anto J, Baena-Cagnani CE, Bergmann KC, Bieber T, Briggs AH, Brozek J, Calderon MA, Dahl R, Devillier P, Gerth van Wijk R, Howarth P, Larenas D, Papadopoulos NG, Schmid-Grendelmeier P, Zuberbier T: How to design and evaluate randomized controlled trials in immunotherapy for allergic rhinitis: an ARIA-GA(2) LEN statement. Allergy. 2011, 66 (6): 765-774. 10.1111/j.1398-9995.2011.02590.x.CrossRefPubMed
57.
Calderón M, Cardona V, Demoly P: EAACI 100 Years of Immunotherapy Experts Panel. One hundred years of allergen immunotherapy European Academy of Allergy and Clinical Immunology celebration: review of unanswered questions. Allergy. 2012, 67 (4): 462-476. 10.1111/j.1398-9995.2012.02785.x.CrossRefPubMed
58.
Calderón MA, Casale TB, Togias A, Bousquet J, Durham SR, Demoly P: Allergen-specific immunotherapy for respiratory allergies: from meta-analysis to registration and beyond. J Allergy Clin Immunol. 2011, 127 (1): 30-38. 10.1016/j.jaci.2010.08.024.CrossRefPubMed
59.
Jacobsen L, Wahn U, Bilo MB: Allergen-specific immunotherapy provides immediate, long-term and preventive clinical effects in children and adults: the effects of immunotherapy can be categorised by level of benefit -the centenary of allergen specific subcutaneous immunotherapy. Clin Transl Allergy. 2012, 2: 8-10.1186/2045-7022-2-8.PubMedCentralCrossRefPubMed
Metadata
Title
EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy
Authors
Moises A Calderon
Pascal Demoly
Roy Gerth van Wijk
Jean Bousquet
Aziz Sheikh
Anthony Frew
Glenis Scadding
Claus Bachert
Hans J Malling
Rudolph Valenta
Beatrice Bilo
Antonio Nieto
Cezmi Akdis
Jocelyne Just
Carmen Vidal
Eva M Varga
Emilio Alvarez-Cuesta
Barbara Bohle
Albrecht Bufe
Walter G Canonica
Victoria Cardona
Ronald Dahl
Alain Didier
Stephen R Durham
Peter Eng
Montserrat Fernandez-Rivas
Lars Jacobsen
Marek Jutel
Jörg Kleine-Tebbe
Ludger Klimek
Jan Lötvall
Carmen Moreno
Ralph Mosges
Antonella Muraro
Bodo Niggemann
Giovanni Pajno
Giovanni Passalacqua
Oliver Pfaar
Sabina Rak
Gianenrico Senna
Gabriela Senti
Erkka Valovirta
Marianne van Hage
Johannes C Virchow
Ulrich Wahn
Nikolaos Papadopoulos
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Clinical and Translational Allergy / Issue 1/2012
Electronic ISSN: 2045-7022
DOI
https://doi.org/10.1186/2045-7022-2-20

Other articles of this Issue 1/2012

Clinical and Translational Allergy 1/2012 Go to the issue

Research

Rhinovirus-induced basic fibroblast growth factor release mediates airway remodeling features

Research

Repeated allergen exposure reduce early phase airway response and leukotriene release despite upregulation of 5-lipoxygenase pathways

Review

FAST: towards safe and effective subcutaneous immunotherapy of persistent life-threatening food allergies

Review

Allergen-specific immunotherapy provides immediate, long-term and preventive clinical effects in children and adults: the effects of immunotherapy can be categorised by level of benefit -the centenary of allergen specific subcutaneous immunotherapy

Research

Intact skin and not stripped skin is crucial for the safety and efficacy of peanut epicutaneous immunotherapy (EPIT) in mice

Review

Mechanisms of allergen-specific immunotherapy